If you and your doctor determine that it is appropriate to seek GLP-1 medications for weight management, it is important to avoid compounded versions of GLP-1 drugs unless your health care provider specifically recommends them
Tirzepatide is a dual-agonist (GLP-1 + GIP)
Our study shows that adoption of GLP-1 agonists changes both the amount and types of food people eat, Lusk said
Clinicians have label information, established warnings, and practical experience with missed doses, dose interruptions, side effects, and glucose monitoring
Gastrointestinal side effects: Nausea or reduced appetite might temporarily lower libido or sexual performance
If patients receive GLP1 medications outside their primary health system (for example, from telehealth) or change providers during the treatment, the EHR data collected in our study may not capture the full course of treatment, and this may explain our observation of generally shorter treatment durations, and hence less weight loss, recorded in EHRs